|
|
Newsletters 07 Sett. 2016
|
|
|
|
Huntington's disease news
|
|
|
|
|
|
|
Ago 24, 2016
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat patients with cancer and neurodegenerative diseases, today announced that its lead antibody product candidate, VX15, which is currently being investigated in a Phase 2 clinical trial for the treatment of Huntington’s disease (the “SIGNAL” trial), has received Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”).
|
|
Ago 24, 2016
Novel Gene Therapy Drug for Huntington’s Disease
Data from Vybion on a novel treatment for Huntington’s disease has been published in the Journal of Neurodegenerative diseases. The published study (http://www.hindawi.com/journals/jnd/2016/7120753/) links the ability of Vybion’s proprietary, novel Intrabody (INT41) blocking of cellular gene dysregulation to the delay of cognitive and motor function loss in the well-validated vR6/2 animal model..
|
|
Ago 19, 2016
Deutetrabenazine for Huntington’s disease: a positive trial but the FDA says no? Not exactly…
A scientific paper declares positive results for a trial of deutetrabenazine in Huntington’s disease, but the headlines report the FDA has rejected the drug. Confusing stuff! The reality is positive overall for this new way of treating uncontrollable movements in HD, but patience will be needed to see where it all ends up.
|
|
Ago 10, 2016
A support system gone wrong – glial cells contribute to HD symptoms
A new piece of research has implicated a type of brain cells called glia in the development of HD symptoms. Regular mice injected with glial cells carrying the mutant huntingtin gene in the study developed symptoms associated with HD. Interestingly, this influence appears to work both ways — a mild reduction in disease symptoms was seen when HD mice were treated with normal glial cells.
|
|
|
|
|
|
|
|